Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
Authors:
Open Access
- 2 November 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (47) , 77482-77494
Abstract
Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patientsKeywords
This publication has 25 references indexed in Scilit:
- Autoimmune response to PARP and BRCA1/BRCA2 in cancerOncotarget, 2015
- Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapyCancer Chemotherapy and Pharmacology, 2014
- Platinum drugs and DNA repair mechanisms in lung cancer.2014
- Histone deacetylases inhibitor trichostatin A modulates the extracellular release of APE1/Ref-1Biochemical and Biophysical Research Communications, 2013
- Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung CancerCurrent Medicinal Chemistry, 2012
- The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentNature Reviews Clinical Oncology, 2012
- Identification of Three New Autoantibodies Associated with Systemic Lupus Erythematosus Using Two Proteomic ApproachesMolecular & Cellular Proteomics, 2011
- APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cellsLung Cancer, 2009
- Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositisInternational Journal of Cancer, 2005
- Elements in abasic site recognition by the major human and Escherichia coli apurinic/apyrimidinic endonucleasesNucleic Acids Research, 1998